바이오미아 퓨전BMEA 주가

Biomea Fusion to Participate at Upcoming Investor Conferences

SAN CARLOS, Calif., May 12, 2026 -- Biomea Fusion, Inc. , a clinical-stage diabetes and obesity company, today announced that management will participate in the following investor conferences: ...

Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism

Biomea Fusion Q1 2026 beat estimates with a smaller-than-expected loss, driven by cost cuts. Pipeline progress includes obesity and diabetes data readouts expected in Q2 and Q4 2026.

Biomea Fusion Q1 EPS $(0.17) Beats $(0.24) Estimate

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.24) by 29.17 percent. This is a 78.75 percent increase over losses of $(0.80) per share from the

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to...

[8-K] 중대 사건 — 8-K

[10-Q] 분기 실적 — 10-Q

Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript

Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights May 5, 2026 2:30 PM EDTCompany...

Transcript : Biomea Fusion, Inc. - Special Call

Presenter SpeechMichael King All right. Good afternoon, everybody. Thank you for joining us this afternoon for what I believe will be an informative and lively discussion with our guest KOL, Dr.

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans. The presentations include data from icovamenib, the Company’s investigational oral menin inhibitor

Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026

Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on tre